Dow Up0.51% Nasdaq Up0.24%

IGI, Laboratories, Inc. (IG)

9.38 Down 0.03(0.32%) Nov 21, 4:00PM EST
ProfileGet Profile for:
IGI, Laboratories, Inc.
105 Lincoln Avenue
Buena, NJ 08310
United States - Map
Phone: 856-697-1441

Index Membership:N/A
Full Time Employees:52

Business Summary 

IGI Laboratories, Inc. develops, manufactures, and markets topical formulations in the United States. The company sells its generic topical pharmaceutical products under the IGI label. It also develops, manufactures, fills, and packages topical semi-solid and liquid products for branded and generic pharmaceutical customers, as well as for over-the-counter (OTC) and cosmetic markets. The company’s products are used in various applications from cosmetics and cosmeceuticals to the prescription treatment of conditions, such as dermatitis, psoriasis, and eczema. In addition, it offers pharmaceutical contract services comprising formulating, testing, and/or manufacturing prescription pharmaceutical products and medical devices; and contract development services consisting of developing topical formulations for the pharmaceutical, OTC, and cosmetic customers. IGI Laboratories, Inc. has a license agreement with Novavax, Inc. to utilize the Novasome lipid vesicle encapsulation and certain other technologies for applications in animal pharmaceuticals, biologicals, and other animal health products; foods, food applications, nutrients, and flavorings; cosmetics, consumer products, and dermatological OTC and prescription products; fragrances; and chemicals, including herbicides, insecticides, pesticides, paints and coatings, photographic chemicals, and other specialty chemicals. The company was formerly known as IGI, Inc. and changed its name to IGI Laboratories, Inc. in May 2008. IGI Laboratories, Inc. was founded in 1977 and is headquartered in Buena, New Jersey.

Key Statistics

Company Websites 
Home Page
Search Yahoo! for:
More on IGI, Laboratories, Inc.

Corporate Governance 
IGI, Laboratories, Inc.’s ISS Governance QuickScore as of Nov 1, 2014 is 7. The pillar scores are Audit: 1; Board: 8; Shareholder Rights: 2; Compensation: 9.
Brought to you by Institutional Shareholder Services (ISS)

Key Executives 
Mr. Jason Grenfell-Gardner , 39
Chief Exec. Officer, Pres and Director
Mrs. Jenniffer L. Collins , 45
Chief Financial Officer, Principal Accounting Officer and Sec.
Bruce Epley ,
Director of Operations
Ms. Nadya Lawrence , 45
Exec. VP of Sales and Marketing
Ms. Justine Kostka , 60
Assistant Controller
Amounts are as of Dec 31, 2013 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
Currency in USD.
View Insiders